metformin has been researched along with Carcinoma, Ehrlich Tumor in 3 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
Carcinoma, Ehrlich Tumor: A transplantable, poorly differentiated malignant tumor which appeared originally as a spontaneous breast carcinoma in a mouse. It grows in both solid and ascitic forms.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Metformin was shown to reduce lipid peroxidation in irradiated healthy tissues, increase tumor cytotoxicity, downregulate critical pathways involved in tumor progression and proliferation, and enhance tumor apoptosis." | 1.72 | Differential effects of cancer modifying agents during radiation therapy on Ehrlich solid tumor-bearing mice: A comparative investigation of metformin and ascorbic acid. ( Ahmed, MM; Al-Mokaddem, AK; Ali, MA; Aljuaydi, SH; Khalil, HMA; Khalil, MM, 2022) |
| "Metformin has demonstrated anti-tumorigenic effect both in vivo and in vitro in different cancer types." | 1.46 | Metformin augments doxorubicin cytotoxicity in mammary carcinoma through activation of adenosine monophosphate protein kinase pathway. ( Abo Mansour, HE; El-Ashmawy, NE; El-Bahrawy, HA; Khedr, NF, 2017) |
| "Metformin is an anti-diabetic agent and its potential antitumor impact has become the objective of numerous studies." | 1.46 | Metformin enhancing the antitumor efficacy of carboplatin against Ehrlich solid carcinoma grown in diabetic mice: Effect on IGF-1 and tumoral expression of IGF-1 receptors. ( Abo-Elmatty, DM; Ahmed, EA; Helmy, SA; Tawfik, MK, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Ali, MA | 1 |
| Khalil, MM | 1 |
| Al-Mokaddem, AK | 1 |
| Aljuaydi, SH | 1 |
| Ahmed, MM | 1 |
| Khalil, HMA | 1 |
| El-Ashmawy, NE | 1 |
| Khedr, NF | 1 |
| El-Bahrawy, HA | 1 |
| Abo Mansour, HE | 1 |
| Abo-Elmatty, DM | 1 |
| Ahmed, EA | 1 |
| Tawfik, MK | 1 |
| Helmy, SA | 1 |
3 other studies available for metformin and Carcinoma, Ehrlich Tumor
| Article | Year |
|---|---|
Differential effects of cancer modifying agents during radiation therapy on Ehrlich solid tumor-bearing mice: A comparative investigation of metformin and ascorbic acid.
Topics: Animals; Ascorbic Acid; Carcinoma, Ehrlich Tumor; Lipid Peroxidation; Metformin; Mice; Neoplasms | 2022 |
Metformin augments doxorubicin cytotoxicity in mammary carcinoma through activation of adenosine monophosphate protein kinase pathway.
Topics: AMP-Activated Protein Kinases; Animals; Apoptosis; Breast Neoplasms; Carcinoma, Ehrlich Tumor; Cell | 2017 |
Metformin enhancing the antitumor efficacy of carboplatin against Ehrlich solid carcinoma grown in diabetic mice: Effect on IGF-1 and tumoral expression of IGF-1 receptors.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carboplatin; Carcinoma, Ehrlich Tumor; Caspase 3; Cell Li | 2017 |